German firm Evotec AG said it will provide its proprietary fragment-based drug discovery platform EVOlution to US company Cubist Pharmaceuticals until 2010 for its drug discovery against additional antibacterial targets.

EVOlution uses biochemical and biophysical techniques including nuclear magnetic resonance, surface plasmon resonance and X-ray crystallography to screen low molecular weight compounds and fragments.

The platform combines orthogonal screening technologies to screen a more diverse set of biological targets than other fragment screening approaches, as well as screen the fragments in a high-throughput mode.